Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index; 37 of the 51 sources its claims cite were checked for support.

Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors

Open access

Abstract

Purpose: We conducted a phase I/II study to evaluate durvalumab (D; anti-PD-L1) in combination with tremelimumab (T; anti–cytotoxic T-lymphocyte antigen 4) in pediatric patients with relapsed/refractory solid tumors. Patients and methods: The dose-finding phase (phase I) assessed the safety and pharmacokinetics of D+T at two dose levels to determine the recommended phase II dose (RP2D). The primary endpoint for the dose-expansion phase (phase II) was antitumor activity (by Response Evaluation Criteria in Solid Tumors v1.1) at the RP2D. Assessment of circulating cells reflecting immune cell activation was a secondary endpoint. Results: Based on safety and pharmacokinetic data in the dose-finding phase (n = 29), the adult-equivalent RP2D was determined as D (30 mg/kg) + T (1 mg/kg). In the dose-expansion phase, 21 patients (sarcoma, n = 11; solid tumors, n = 10) were treated at the RP2D. Of patients with sarcoma, none achieved an objective response and one had stable disease ≥7 weeks. Of the patients with solid tumors, one (chordoma) had a confirmed partial response (10.8 months duration) and one (renal cell carcinoma) had stable disease ≥7 weeks. Treatment-related adverse events occurred in 76% of patients (19% as grade 3 or 4). No adverse events leading to death were reported. Across both phases treatment with D+T resulted in an increase in CD4+Ki67+ T cells. Conclusions: D (30 mg/kg) + T (1 mg/kg) had limited antitumor activity in this pediatric population; however, the safety profile was manageable and consistent with the known safety profile in adult patients, with no new safety concerns identified. Clinical trial registration: ClinicalTrials.gov, identifier NCT03837899; EudraCT, identifier 2018-003118-42.

Overview

CoChat Summary

TL;DR

In pediatric patients with relapsed/refractory advanced solid tumors, durvalumab 30 mg/kg plus tremelimumab 1 mg/kg was selected as the adult-equivalent recommended phase II dose, with a manageable safety profile but limited antitumor activity. In the dose-expansion phase, the objective response rate was 5.0% among 20 evaluable patients, with one confirmed partial response in chordoma lasting 10.8 months.

Key findings

  • The recommended phase II dose was durvalumab 30 mg/kg plus tremelimumab 1 mg/kg every 4 weeks, based on safety and pharmacokinetic data from 29 patients in the dose-finding phase.
  • In the dose-expansion phase (n = 21; sarcoma n = 11, solid tumors n = 10), no sarcoma patient achieved an objective response; one sarcoma patient had stable disease ≥7 weeks. Among solid tumor patients, one chordoma patient had a confirmed partial response lasting 10.8 months and one renal cell carcinoma patient had stable disease ≥7 weeks.
  • The ORR in the dose-expansion phase was 5.0% among 20 evaluable patients. Median PFS was 1.7 months in both the sarcoma cohort (90% CI, 1.6–1.9) and the solid tumor cohort (90% CI, 0.9–2.8); median OS was 6.6 months (90% CI, 1.9–15.8) and 6.9 months (90% CI, 1.6–not reached), respectively.
  • Treatment-related adverse events occurred in 76% of dose-expansion patients, with 19% grade 3 or 4; no adverse events leading to death were reported. Across both phases, treatment increased CD4+Ki67+ T cells, with a transient rise at day 8 in 100% of evaluable patients.

Methods

  • Open-label, international, multicenter phase I/II study in pediatric patients aged ≥1 to <18 years with relapsed/refractory malignant solid tumors, enrolled at 19 sites in seven countries from March 2019 through May 2022.
  • Dose-finding used a modified 3 + 3 design incorporating pharmacokinetic exposure and dose-limiting toxicities to determine the RP2D; dose-expansion used a Simon-2 stage design for the sarcoma cohort and descriptive statistics for the heterogeneous solid tumor cohort.
  • Primary endpoints were RP2D/safety in dose-finding and antitumor activity by RECIST v1.1 in dose-expansion; analyses were descriptive, with 90% CIs unless otherwise stated, exact Mid-P method for ORR, and Kaplan–Meier methods for PFS and OS.

Limitations

  • The paper states that limited enrollment meant demographics were not reflective of a global pediatric population, with Black and Asian patients under-represented.
  • The paper states that cross-trial comparisons with prior ICI studies are limited, and that conclusions about immune response differences between pediatric and adult patients are limited by overlapping CIs and small sample size.
  • Evident from the text: this was a single-arm, open-label study without a comparator; dose-expansion cohorts were small (sarcoma n = 11, solid tumors n = 10), median treatment durations were short (1.84 and 1.72 months), and PD-L1 biomarker analysis was exploratory with only 27 evaluable tumor samples.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.3389/fonc.2026.1680081

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Kaplan-Meier plot of overall survival for patients in the dose-expansion phase. Median OS (90% confidence interval) was 6.6 months (1.9–15.8) in the sarcoma cohort (8 events among 11 patients), 6.9 months (1.6–not reached) in the solid tumors cohort (7 events among 10 patients), and 6.6 months (2.3–12.5) for all patients (15 events among 21 patients). Circles indicate censored observations.
Figure 1 Kaplan-Meier plot of overall survival for patients in the dose-expansion phase. Median OS (90% confidence interval) was 6.6 months (1.9–15.8) in the sarcoma cohort (8 events among 11 patients), 6.9 months (1.6–not reached) in the solid tumors cohort (7 events among 10 patients), and 6.6 months (2.3–12.5) for all patients (15 events among 21 patients). Circles indicate censored observations.CC BY · PubMed Central
Figure 2 Swimmer plot of best overall response by tumor PD-L1 expression and tumor type. PD-L1 expression was assessed by immunohistochemistry in pretreatment tumor tissue samples using the investigational VENTANA PD-L1 (SP263) Assay (Roche Diagnostics, Tucson, AZ, USA). PD-L1 expression was scored using a TAP score (16), which was determined by visually aggregating/estimating the area covered by PD-L1–positive tumor cells and tumor-associated immune cells relative to the total tumor area, using a cutoff of 10%. *For the patient with renal cell carcinoma, although the last tumor assessment was recorded as stable disease, the investigator confirmed that the patient was still in response (partial response) at the time of study closure. §Not evaluable. PD-L1, programmed death ligand 1.
Figure 2 Swimmer plot of best overall response by tumor PD-L1 expression and tumor type. PD-L1 expression was assessed by immunohistochemistry in pretreatment tumor tissue samples using the investigational VENTANA PD-L1 (SP263) Assay (Roche Diagnostics, Tucson, AZ, USA). PD-L1 expression was scored using a TAP score (16), which was determined by visually aggregating/estimating the area covered by PD-L1–positive tumor cells and tumor-associated immune cells relative to the total tumor area, using a cutoff of 10%. *For the patient with renal cell carcinoma, although the last tumor assessment was recorded as stable disease, the investigator confirmed that the patient was still in response (partial response) at the time of study closure. §Not evaluable. PD-L1, programmed death ligand 1.CC BY · PubMed Central

Verification

Claims the paper makes

26 Valid · 3 Not valid · 5 Not checked · 89 Own results and interpretations

52 more claims · 5 with their cited sources checked

Create a free account to see all 123 claims and every source verdict.

See all claims — free account
  • It may state two separate claims as one. 56
  • Probably not a substantial claim. 15
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

2 of 2

Citations

Cites

Show all 27 references

Cited by

See all 1

Metadata

Authors
Hargrave, D., Marshall, L. V., André, N., Krystal, J., Ladle, B. H., Robbins, K. A., Hois, S., Armstrong, J., & Donegan, S.
Affiliations
  • Great Ormond Street Hospital (GB)
  • Institute of Cancer Research (GB)
  • Pediatric Hematology and Oncology Department, Hôpital pour Enfant de La Timone, Assistance Publique - Hôpitaux de Marseille (AP-HM), and Reverse Molecular Pharmacology in Pediatric Oncology, Centre de Recherche en Cancérologie de Marseille (CRCM), Aix-Marseille Université, CNRS, INSERM
  • Cohen Children's Medical Center (US)
  • Johns Hopkins University (US)
  • Global Patient Safety, Oncology, AstraZeneca
  • Late-stage Development Oncology R&D, AstraZeneca
  • Oncology Biometrics
  • Oncology R&D, AstraZeneca
Corresponding author
Hargrave, Darren
Venue
Frontiers in Oncology
Published
2026-05-15
Volume
16
Pages
1680081-1680081
ISSN
2234-943X (ISSN-L)
OpenAlex
W7161272841
Cited by
1
References
27
Citations by year
2026: 1
FWCI
2.94
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Oncology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Health Sciences › Medicine › Oncology › CAR-T cell therapy research
Keywords
durvalumab, tremelimumab, PD-L1 inhibitors, CTLA-4 blockade, immune checkpoint inhibitors, combination immunotherapy, pediatric solid tumors, relapsed/refractory cancer, sarcoma, chordoma, renal cell carcinoma, dose-finding, recommended phase 2 dose, anticancer activity, treatment safety, immune cell activation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors. https://app.cochat.ai/papers/10.3389/fonc.2026.1680081
The paper
Hargrave, D., Marshall, L. V., André, N., Krystal, J., Ladle, B. H., Robbins, K. A., Hois, S., Armstrong, J., & Donegan, S. (2026). Phase I/II, open-label, multicenter study of durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors. Frontiers in Oncology. https://doi.org/10.3389/fonc.2026.1680081

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.